Merus NV (MRUS)

Currency in USD
64.00
+0.61(+0.96%)
Closed·
After Hours
64.000.00(0.00%)
·
MRUS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MRUS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
63.0064.00
52 wk Range
33.1967.59
Key Statistics
Prev. Close
63.39
Open
63.8
Day's Range
63-64
52 wk Range
33.19-67.59
Volume
557.24K
Average Volume (3m)
1.12M
1-Year Change
27.97%
Book Value / Share
11.3
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MRUS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
90.40
Upside
+41.25%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Merus NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Merus NV Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Merus NV SWOT Analysis


Pipeline Promise
Merus N.V.'s innovative antibody therapies for cancer treatment show potential, with lead candidates petosemtamab and zenocutuzumab demonstrating promising clinical results
Financial Outlook
Analysts project revenue growth to $525.9M by 2027, with EPS turning positive. Current price targets range from $67 to $109, reflecting bullish sentiment
Market Positioning
Explore Merus's unique position in oncology drug development, leveraging its proprietary Biclonics® technology to potentially capture a significant market share
Growth Catalysts
Delve into Merus's future prospects, including potential accelerated approvals, strategic partnerships, and pipeline expansion opportunities in the competitive oncology landscape
Read full SWOT analysis

Compare MRUS to Peers and Sector

Metrics to compare
MRUS
Peers
Sector
Relationship
P/E Ratio
−12.6x−1.4x−0.5x
PEG Ratio
0.140.000.00
Price/Book
5.8x2.7x2.6x
Price / LTM Sales
86.1x8.3x3.3x
Upside (Analyst Target)
43.8%179.7%43.5%
Fair Value Upside
Unlock6.9%6.8%Unlock

Analyst Ratings

17 Buy
0 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 90.40
(+41.25% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-2.23 / -1.16
Revenue / Forecast
8.83M / 13.47M
EPS Revisions
Last 90 days

MRUS Income Statement

People Also Watch

247.45
AVAV
-4.68%
91.98
RYTM
-0.54%
27.37
VCYT
-1.12%
109.55
INSM
+0.23%
191.49
ASND
+0.60%

FAQ

What Stock Exchange Does Merus Trade On?

Merus is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Merus?

The stock symbol for Merus is "MRUS."

What Is the Merus Market Cap?

As of today, Merus market cap is 4.84B.

What Is Merus's Earnings Per Share (TTM)?

The Merus EPS (TTM) is -5.57.

When Is the Next Merus Earnings Date?

Merus will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is MRUS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Merus Stock Split?

Merus has split 0 times.

How Many Employees Does Merus Have?

Merus has 291 employees.

What is the current trading status of Merus (MRUS)?

As of 09 Aug 2025, Merus (MRUS) is trading at a price of 64.00, with a previous close of 63.39. The stock has fluctuated within a day range of 63.00 to 64.00, while its 52-week range spans from 33.19 to 67.59.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.